Amarin Corporation PLC (NASDAQ: AMRN) is a pharmaceutical company that develops and commercializes a single prescription product, VASCEPA (icosapentaenoic acid, also marketed as VAZKEPA in certain markets), an omega-3 fatty acid therapy indicated for cardiovascular risk reduction. Revenue comes from two streams: direct product sales to wholesalers in the U.S. and select international markets, and licensing and royalty payments from commercial partners who distribute VASCEPA in territories including Europe, Canada, the Middle East, North Africa, Australia, New Zealand, Southeast Asia, Greece, and Israel. Direct sales carry higher gross margins than partner-channel sales, because Amarin bears the full promotional cost but captures the full net price. The company executed a June 2025 Global Restructuring Plan, incurring severance and contract-related charges, signaling a material reduction in its operating footprint. Amarin operates under a single-product model with concentrated dependence on VASCEPA's commercial performance across multiple regulatory jurisdictions.

Revenue model

Two revenue streams per the FY2025 10-K: (1) product revenue from direct VASCEPA sales to wholesalers in the U.S. and select international markets, recognized at delivery; (2) licensing and royalty revenue from upfront payments, milestone payments, and sales-based royalties under license and distribution agreements with international partners including Recordati (59 countries, Europe-focused), HLS Therapeutics (Canada), Biologix (Middle East and North Africa), CSL Seqirus (Australia and New Zealand), Lotus Pharmaceuticals (Southeast Asia), Vianex (Greece), and Neopharm (Israel).

Products and services

VASCEPA (branded VAZKEPA in Europe and certain other markets): a prescription omega-3 fatty acid (icosapentaenoic acid) therapy. This is the company's sole commercial product as of the FY2025 10-K filing date.

Customers and end markets

U.S. channel: wholesalers and distributors who supply retail and specialty pharmacies; end patients are those with cardiovascular risk managed by prescribing physicians. International channel: commercial partners (Recordati, HLS, Biologix, CSL Seqirus, Lotus, Vianex, Neopharm) who bear promotional costs and resell to local distributors and pharmacies. Payors include Medicare, Medicaid, and private insurers in the U.S., with analogous reimbursement bodies in international markets.

Value-chain role

Amarin holds the IP and regulatory approvals for VASCEPA/VAZKEPA and acts as manufacturer-of-record or supply-chain principal, supplying product to both direct wholesaler customers and third-party commercial partners. In international licensed territories, Amarin's role is limited to product supply and IP licensing; all local promotion and distribution is handled by partners. The company does not operate retail or hospital-direct channels.

Geographic exposure

United States (direct commercial operations), Europe (Recordati license, 59 countries), Canada (HLS Therapeutics), United Arab Emirates, Lebanon, Kuwait, Saudi Arabia (Biologix), Australia and New Zealand (CSL Seqirus), Southeast Asia (Lotus Pharmaceuticals), Greece (Vianex), Israel (Neopharm). Per the FY2025 10-K, international revenue is subject to foreign exchange exposure and partner execution risk.

Source: SEC 10-K, filed 2026-03-02

Industry: Pharmaceutical Preparations Peers: Alkermes Plc Horizon Therapeutics Public Ltd Co Prothena Corporation PLC